Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas December 7, 2020
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL) December 4, 2020
Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 Clinical Trial Evaluating RIVAL-01 For the Treatment of Solid Tumors December 1, 2020
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer December 1, 2020
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020 November 22, 2020
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD) November 19, 2020
Caribou Biosciences Announces Licensing Agreement for scFvs Targeting CD371 to Enable Development of Allogeneic Cell Therapies November 18, 2020
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH November 16, 2020